Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
Conditions: Metastic Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Second-line Treatment Interventions: Biological: SHR-1210; Biological: CIK cells Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Hospitals | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Research | Study